LA JOLLA, Calif., March 5 /PRNewswire/ -- Advanced Tissue Sciences, Inc.
(Nasdaq: ATIS) announced that Dr. Gail K. Naughton, President and Chief
Operating Officer and Dr. Joan Zeltinger, Sr. Research Scientist, both of
Advanced Tissue Sciences, will present on recent advances in tissue
engineering small diameter vascular grafts. Their presentation of this
scientific data will be made at the International Society for Applied
Cardiovascular Biology in Munich, Germany on March 6, 1998.
Tissue engineered vascular grafts are being developed to repair or replace
segments of arterial and venous blood vessels that are weakened, damaged or
obstructed due to trauma or disease. Unlike traditional devices, tissue
engineered vascular grafts are designed to remain biologically interactive
after implantation, thereby providing the physiologic functions of the
replaced tissue as well as structure. Advanced Tissue Sciences' approach to
tissue engineering involves the use of completely closed bioreactor systems to
maintain sterility while mimicking a physiological environment in which cells,
seeded onto biocompatible, three-dimensional scaffolds, divide and secrete
structural matrix proteins and bioactive molecules, such as human growth
factors, to form a functional tissue.
Advanced Tissue Sciences, Inc. is a tissue engineering company utilizing
its proprietary core technology to develop and manufacture human tissue
products for tissue repair and transplantation. The Company currently has two
products in the market: Dermagraft(R), a living, permanent dermal replacement
for the treatment of diabetic foot ulcers, and Dermagraft-TC(TM), a temporary
covering for full and partial-thickness burns. In addition to Dermagraft and
Dermagraft-TC, the Company also is developing products for cartilage and
cardiovascular applications.
For the most current news on Advanced Tissue Sciences, visit the Company's
web site at http://www.advancedtissue.com.
This press release includes a number of forward-looking statements
including, but not limited to, statements with respect to the development and
commercialization of products and potential therapeutic benefits. Such
statements involve risks and uncertainties. No assurance can be given that
the Company will successfully develop such products, obtain regulatory
approvals of such products (or that any such approvals will be obtained on a
timely basis), complete clinical trials, scale up manufacturing processes,
launch products within specified timeframes, or commercialize or significantly
penetrate the markets for any product. These and other risks are detailed in
the Company's publicly available filings with the Securities and Exchange
Commission, including its Annual Report on Form 10-K. Actual results may
differ materially from those currently anticipated as a result of such risks.
SOURCE Advanced Tissue Sciences, Inc.
 back to top
Related links:
http://www.advancedtissue.com
CONTACT:
Investors: Beth A. Kriegel, Director,
Investor Relations, 619-450-5802, or Media: Janet M. Wahl,
Director, Corporate Communications, 619-657-5909
|
